Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models
Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have previously described the physicochemical characteristics and the in vitro anticancer properties of a multifunctional doxorubicin-loaded lipos...
Saved in:
Published in | Cancer biology & therapy Vol. 15; no. 1; pp. 69 - 80 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Taylor & Francis
01.01.2014
Landes Bioscience |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have previously described the physicochemical characteristics and the in vitro anticancer properties of a multifunctional doxorubicin-loaded liposomal formulation. Lipodox
®
, a commercially available PEGylated liposomal doxorubicin, was made multifunctional by surface-decorating with a cell-penetrating peptide, TATp, conjugated to PEG
1000
-PE, to enhance liposomal cell uptake. A pH-sensitive polymer, PEG
2000
-Hz-PE, with a pH-sensitive hydrazone (Hz) bond to shield the peptide in the body and expose it only at the acidic tumor cell surface, was used as well. In addition, an anti-nucleosome monoclonal antibody 2C5 attached to a long-chain polymer to target nucleosomes overexpressed on the tumor cell surface was also present. Here, we report the in vitro cell uptake and cytotoxicity of the modified multifunctional immunoliposomes as well as the in vivo studies on tumor xenografts developed subcutaneously in nude mice with MDR and drug-sensitive human ovarian cancer cells (SKOV-3). Our results show the ability of multifunctional immunoliposomes to overcome MDR by enhancing cytotoxicity in drug-resistant cells, compared with non-modified liposomes. Furthermore, in comparison with the non-modified liposomes, upon intravenous injection of these multifunctional immunoliposomes into mice with tumor xenografts, a significant reduction in tumor growth and enhanced therapeutic efficacy of the drug in both drug-resistant and drug-sensitive mice was obtained. The use of "smart" multifunctional delivery systems may provide the basis for an effective strategy to develop, improve, and overcome MDR cancers in the future. |
---|---|
AbstractList | Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have previously described the physicochemical characteristics and the in vitro anticancer properties of a multifunctional doxorubicin-loaded liposomal formulation. Lipodox
®
, a commercially available PEGylated liposomal doxorubicin, was made multifunctional by surface-decorating with a cell-penetrating peptide, TATp, conjugated to PEG
1000
-PE, to enhance liposomal cell uptake. A pH-sensitive polymer, PEG
2000
-Hz-PE, with a pH-sensitive hydrazone (Hz) bond to shield the peptide in the body and expose it only at the acidic tumor cell surface, was used as well. In addition, an anti-nucleosome monoclonal antibody 2C5 attached to a long-chain polymer to target nucleosomes overexpressed on the tumor cell surface was also present. Here, we report the in vitro cell uptake and cytotoxicity of the modified multifunctional immunoliposomes as well as the in vivo studies on tumor xenografts developed subcutaneously in nude mice with MDR and drug-sensitive human ovarian cancer cells (SKOV-3). Our results show the ability of multifunctional immunoliposomes to overcome MDR by enhancing cytotoxicity in drug-resistant cells, compared with non-modified liposomes. Furthermore, in comparison with the non-modified liposomes, upon intravenous injection of these multifunctional immunoliposomes into mice with tumor xenografts, a significant reduction in tumor growth and enhanced therapeutic efficacy of the drug in both drug-resistant and drug-sensitive mice was obtained. The use of “smart” multifunctional delivery systems may provide the basis for an effective strategy to develop, improve, and overcome MDR cancers in the future. Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have previously described the physicochemical characteristics and the in vitro anticancer properties of a multifunctional doxorubicin-loaded liposomal formulation. Lipodox(®), a commercially available PEGylated liposomal doxorubicin, was made multifunctional by surface-decorating with a cell-penetrating peptide, TATp, conjugated to PEG 1000-PE, to enhance liposomal cell uptake. A pH-sensitive polymer, PEG 2000-Hz-PE, with a pH-sensitive hydrazone (Hz) bond to shield the peptide in the body and expose it only at the acidic tumor cell surface, was used as well. In addition, an anti-nucleosome monoclonal antibody 2C5 attached to a long-chain polymer to target nucleosomes overexpressed on the tumor cell surface was also present. Here, we report the in vitro cell uptake and cytotoxicity of the modified multifunctional immunoliposomes as well as the in vivo studies on tumor xenografts developed subcutaneously in nude mice with MDR and drug-sensitive human ovarian cancer cells (SKOV-3). Our results show the ability of multifunctional immunoliposomes to overcome MDR by enhancing cytotoxicity in drug-resistant cells, compared with non-modified liposomes. Furthermore, in comparison with the non-modified liposomes, upon intravenous injection of these multifunctional immunoliposomes into mice with tumor xenografts, a significant reduction in tumor growth and enhanced therapeutic efficacy of the drug in both drug-resistant and drug-sensitive mice was obtained. The use of "smart" multifunctional delivery systems may provide the basis for an effective strategy to develop, improve, and overcome MDR cancers in the future. |
Author | Koren, Erez Apte, Anjali Torchilin, Vladimir P Koshkaryev, Alexander |
Author_xml | – sequence: 1 givenname: Anjali surname: Apte fullname: Apte, Anjali – sequence: 2 givenname: Erez surname: Koren fullname: Koren, Erez – sequence: 3 givenname: Alexander surname: Koshkaryev fullname: Koshkaryev, Alexander – sequence: 4 givenname: Vladimir P surname: Torchilin fullname: Torchilin, Vladimir P email: v.torchilin@neu.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24145298$$D View this record in MEDLINE/PubMed |
BookMark | eNplkcuOFCEUhokZ41x04QsYlrqoESioy8ZkMl6TSdy0a8LlVM8xVdAC1dpv5GPK2ONEY0LC5f_Oz4H_nJyEGICQ55xdSt7x186WS9F1bHxEzrhSqhlU353crduhkUz2p-Q856-MiV504xNyKiSXSozDGfn5Nv6IabXoMNA6NlcbuoNdQQ_NEj1OCJ4u61xwWoMrGIOZKS7LGuKMu5jjApl6WGLIJZlSNxhcApNrman8HsuBmq3BqlMbyy31ad02GULGqgI1wR-PEmTMxYRC494kNIE6ExwkWtuAOT8ljyczZ3h2P1-QL-_fba4_NjefP3y6vrppnBSsNKNyXhjjO6fADqzj3E6y4zD0XjAhpbWOwciByaEF3_YTTNxy1feTG4Qd-_aCvDn67la7gHcQ6rtmvUu4mHTQ0aD-Vwl4q7dxr9uxHZRQ1eDlvUGK31bIRS-YHcyzCRDXrLkc237sOiUq-uqIuhRzTjA9XMOZvktW12T172Qr--Lvvh7IP1FWQB4BDFNMi_ke0-x1MYc5pinVr8Ss2_99fwHpALox |
CitedBy_id | crossref_primary_10_1002_bip_22678 crossref_primary_10_4161_tisb_29528 crossref_primary_10_1007_s10529_014_1497_2 crossref_primary_10_2174_1566523223666230601145632 crossref_primary_10_2174_1573394716666200227095521 crossref_primary_10_1007_s13204_018_0776_y crossref_primary_10_1021_acsami_5b06488 crossref_primary_10_1016_j_jconrel_2022_08_001 crossref_primary_10_1080_01635581_2015_1002624 crossref_primary_10_3390_ph12020081 crossref_primary_10_1007_s11705_015_1538_y crossref_primary_10_1021_acsnano_8b06104 crossref_primary_10_3923_ijp_2022_70_78 crossref_primary_10_3390_ijms21114138 crossref_primary_10_1007_s40495_016_0056_z crossref_primary_10_1016_j_ijpharm_2015_04_059 crossref_primary_10_1080_10717544_2018_1435747 crossref_primary_10_1517_17425247_2016_1125879 crossref_primary_10_1016_j_colsurfb_2015_07_013 crossref_primary_10_1016_j_nano_2020_102309 crossref_primary_10_1016_j_mtbio_2022_100248 crossref_primary_10_1089_cbr_2018_2447 crossref_primary_10_2174_1567201817666200708113131 crossref_primary_10_1016_j_xphs_2021_08_015 crossref_primary_10_1517_17425247_2015_1086745 crossref_primary_10_1007_s13346_018_00606_x crossref_primary_10_1016_j_jics_2021_100119 crossref_primary_10_3390_pharmaceutics13091391 crossref_primary_10_3390_ijms19030731 crossref_primary_10_1016_j_ijpharm_2020_120117 crossref_primary_10_1016_j_jconrel_2023_09_016 crossref_primary_10_1038_nrd4333 crossref_primary_10_1080_17425247_2017_1247804 crossref_primary_10_3390_pr7100727 crossref_primary_10_1016_j_xphs_2018_12_016 crossref_primary_10_1016_j_jconrel_2016_02_008 crossref_primary_10_1016_j_omtn_2019_07_014 crossref_primary_10_2174_1568026620666200128142603 crossref_primary_10_1016_j_cbi_2017_09_006 crossref_primary_10_1021_acs_chemrev_5b00046 crossref_primary_10_1016_j_phrs_2020_105231 crossref_primary_10_1039_C8NH00417J |
Cites_doi | 10.1016/S0076-6879(03)72019-9 10.1016/0005-2736(94)90003-5 10.1016/0169-409X(95)00022-Y 10.1016/S0168-3659(01)00330-3 10.1515/BC.2003.044 10.1016/j.ijpharm.2009.02.022 10.1007/BF00046364 10.1126/science.8128245 10.1021/bc060080h 10.1021/bc0155061 10.1021/bc025517+ 10.1016/S0168-3659(01)00309-1 10.1016/j.addr.2012.08.009 10.1158/1078-0432.CCR-08-2392 10.1073/pnas.0931428100 10.1021/mp8001528 10.1021/bc060228x 10.1016/S0005-2728(01)00165-7 10.1038/mt.2008.36 10.1007/s11095-006-9662-5 10.1208/s12248-010-9174-4 10.1080/10717540902937562 10.1016/j.addr.2013.08.004 10.1080/10258140290033066 10.1016/j.bmcl.2005.07.087 10.1016/0014-2999(90)91262-A 10.1016/S0928-0987(00)00166-4 10.1016/j.jhep.2004.12.035 10.1016/0092-8674(88)90263-2 10.1080/10611860701498203 10.1042/BJ20040238 10.1016/S1368-7646(03)00082-7 10.1016/S0168-3659(99)00248-5 10.1124/jpet.107.127704 10.1016/j.ddmec.2004.10.001 10.1073/pnas.151247498 10.1016/j.jconrel.2011.12.002 10.1021/bc900081e 10.1208/s12248-008-9029-4 10.1208/aapsj0902015 10.1016/j.jconrel.2004.08.007 10.1158/1078-0432.CCR-07-4973 10.1038/nrd1632 10.3109/10717544.2011.567310 10.1016/0005-2736(91)90246-5 10.1158/0008-5472.CAN-05-0765 10.1016/j.taap.2004.10.012 10.3727/000000006783980946 10.1039/c2ib20135f 10.1016/S0021-9258(18)37555-0 10.1016/j.ejpb.2008.09.026 10.1016/j.molmed.2012.04.012 |
ContentType | Journal Article |
Copyright | Copyright © 2014 Landes Bioscience 2014 |
Copyright_xml | – notice: Copyright © 2014 Landes Bioscience 2014 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.4161/cbt.26609 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1555-8576 |
EndPage | 80 |
ExternalDocumentID | 10_4161_cbt_26609 24145298 10926609 |
Genre | Research Paper Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA121838 – fundername: NCI NIH HHS grantid: R01 CA128486 |
GroupedDBID | --- 00X 0R~ 0YH 29B 30N 53G 5GY 6J9 AAAVI AAJNR ABBKH ABCCY ABEIZ ABFIM ABJVF ACENM ACGFO ACGFS ACTIO ADBBV ADCVX AECIN AEGYZ AEISY AENEX AEXWM AHDLD AIJEM AIRBT ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS AQRUH AVBZW AWQZV BABNJ BAWUL BLEHA CCCUG DGEBU DIK DKSSO E3Z EBS EJD EMOBN F5P H13 HYE IH2 IPNFZ KSSTO KYCEM M4Z O9- OK1 P2P P6G RIG RPM SJN TFL TFT TFW TR2 TTHFI ZGOLN 0VX 4.4 ACKZS ADFZZ AFPKN AGYJP AURDB BFWEY C1A CGR CUY CVF CWRZV ECM EIF GROUPED_DOAJ LJTGL NPM PCLFJ TDBHL UDS AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c420t-95cd2aad6c5eb80611bf461e87d20244bbc0e91e0483ed37fef1b1577fc82b973 |
IEDL.DBID | RPM |
ISSN | 1538-4047 |
IngestDate | Tue Sep 17 21:26:03 EDT 2024 Sat Oct 05 04:36:06 EDT 2024 Fri Aug 23 03:20:08 EDT 2024 Sat Sep 28 07:52:47 EDT 2024 Tue Jul 04 18:14:25 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | multidrug resistance 2C5 mAb Lipodox doxil SKOV-3 cells TAT peptide pH-sensitive polymers multifunctional immunoliposomes doxorubicin |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c420t-95cd2aad6c5eb80611bf461e87d20244bbc0e91e0483ed37fef1b1577fc82b973 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.tandfonline.com/doi/pdf/10.4161/cbt.26609?needAccess=true |
PMID | 24145298 |
PQID | 1493796652 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | crossref_primary_10_4161_cbt_26609 proquest_miscellaneous_1493796652 informaworld_taylorfrancis_310_4161_cbt_26609 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3938525 pubmed_primary_24145298 |
PublicationCentury | 2000 |
PublicationDate | 2014-01-01 |
PublicationDateYYYYMMDD | 2014-01-01 |
PublicationDate_xml | – month: 01 year: 2014 text: 2014-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Cancer biology & therapy |
PublicationTitleAlternate | Cancer Biol Ther |
PublicationYear | 2014 |
Publisher | Taylor & Francis Landes Bioscience |
Publisher_xml | – name: Taylor & Francis – name: Landes Bioscience |
References | 2292138 - Cancer Metastasis Rev. 1990 Nov;9(3):253-66 21438724 - Drug Deliv. 2011 Jul;18(5):377-84 16168650 - Bioorg Med Chem Lett. 2005 Nov 15;15(22):5071-5 8128245 - Science. 1994 Mar 18;263(5153):1600-3 19446767 - Int J Pharm. 2009 Jun 5;374(1-2):114-8 2065067 - Biochim Biophys Acta. 1991 Jul 1;1066(1):29-36 19601640 - Bioconjug Chem. 2009 Aug 19;20(8):1531-7 15845415 - Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37 9393743 - Cancer Res. 1997 Dec 1;57(23):5246-53 23973912 - Adv Drug Deliv Rev. 2013 Nov;65(13-14):1748-62 15491817 - J Control Release. 2004 Nov 5;100(1):135-44 12715889 - Biol Chem. 2003 Mar;384(3):387-93 17913043 - Oncol Res. 2007;16(8):351-9 22964425 - Adv Drug Deliv Rev. 2013 Jan;65(1):24-35 16848401 - Bioconjug Chem. 2006 Jul-Aug;17(4):943-9 15688077 - Nat Rev Drug Discov. 2005 Feb;4(2):145-60 18483388 - Clin Cancer Res. 2008 May 15;14(10):3193-203 10699287 - J Control Release. 2000 Mar 1;65(1-2):271-84 12378272 - Cell Mol Biol Lett. 2002;7(3):889-94 22682515 - Trends Mol Med. 2012 Jul;18(7):385-93 12121127 - Bioconjug Chem. 2002 Jul-Aug;13(4):729-36 18977297 - Eur J Pharm Biopharm. 2009 Mar;71(3):431-44 19538007 - Drug Deliv. 2009 Jul;16(5):261-7 22182771 - J Control Release. 2012 Jun 10;160(2):264-73 19049322 - Mol Pharm. 2009 Jan-Feb;6(1):246-54 17947497 - J Pharmacol Exp Ther. 2008 Jan;324(1):95-102 18388927 - Mol Ther. 2008 May;16(5):893-900 7641188 - Cancer Res. 1995 Sep 1;55(17):3752-6 3182782 - J Biol Chem. 1988 Nov 5;263(31):16051-4 11716691 - Bioconjug Chem. 2001 Nov-Dec;12(6):995-9 15826724 - J Hepatol. 2005 May;42(5):736-43 15193145 - Biochem J. 2004 Sep 15;382(Pt 3):945-56 14610822 - Methods Enzymol. 2003;372:339-49 11286983 - Biochim Biophys Acta. 2001 Apr 2;1511(2):397-411 17614355 - AAPS J. 2007;9(2):E128-47 16550475 - Pharm Res. 2006 Apr;23(4):752-8 14643297 - Drug Resist Updat. 2003 Oct;6(5):271-9 11489482 - J Control Release. 2001 Jul 6;74(1-3):47-61 16103050 - Cancer Res. 2005 Aug 15;65(16):7045-51 17309227 - Bioconjug Chem. 2007 Mar-Apr;18(2):363-70 19276264 - Clin Cancer Res. 2009 Mar 15;15(6):1973-80 12716967 - Proc Natl Acad Sci U S A. 2003 May 13;100(10):6039-44 11489491 - J Control Release. 2001 Jul 6;74(1-3):147-58 2849510 - Cell. 1988 Dec 23;55(6):1189-93 18587651 - AAPS J. 2008 Jun;10(2):349-59 22869005 - Integr Biol (Camb). 2013 Jan;5(1):96-107 11438707 - Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8786-91 12385965 - J Biochem Mol Biol Biophys. 2002 Oct;6(5):309-14 20143195 - AAPS J. 2010 Jun;12(2):171-80 17671900 - J Drug Target. 2007 Aug-Sep;15(7-8):538-45 11033430 - Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S81-91 7918551 - Biochim Biophys Acta. 1994 Oct 12;1195(1):11-20 R21 Gupta B (R37) 2007; 16 R20 R23 R25 R24 R27 R26 R29 R28 R1 R2 R3 R4 R5 R6 R7 R9 R30 R32 R31 R34 R33 R36 R35 R38 Yuan F (R22) 1995; 55 R39 Elbayoumi T (R54) 2006; 26 Maeda H (R18) 1988; 263 R41 R40 R43 R42 R45 R47 R46 R49 R48 R50 R52 Krishna R (R8) 1997; 57 R51 R10 Allen TM (R44) 2002; 7 R53 R12 R56 R11 R55 R14 R13 R16 R15 R17 R19 |
References_xml | – ident: R35 doi: 10.1016/S0076-6879(03)72019-9 – ident: R23 doi: 10.1016/0005-2736(94)90003-5 – ident: R24 doi: 10.1016/0169-409X(95)00022-Y – ident: R13 doi: 10.1016/S0168-3659(01)00330-3 – ident: R32 doi: 10.1515/BC.2003.044 – volume: 55 start-page: 3752 year: 1995 ident: R22 publication-title: Cancer Res contributor: fullname: Yuan F – ident: R36 doi: 10.1016/j.ijpharm.2009.02.022 – ident: R21 doi: 10.1007/BF00046364 – ident: R2 doi: 10.1126/science.8128245 – volume: 26 start-page: 1 year: 2006 ident: R54 publication-title: Pharmaceutical Engineering contributor: fullname: Elbayoumi T – ident: R41 doi: 10.1021/bc060080h – ident: R48 doi: 10.1021/bc0155061 – ident: R45 doi: 10.1021/bc025517+ – ident: R20 doi: 10.1016/S0168-3659(01)00309-1 – ident: R26 doi: 10.1016/j.addr.2012.08.009 – ident: R56 doi: 10.1158/1078-0432.CCR-08-2392 – ident: R29 doi: 10.1073/pnas.0931428100 – ident: R52 doi: 10.1021/mp8001528 – ident: R40 doi: 10.1021/bc060228x – ident: R28 doi: 10.1016/S0005-2728(01)00165-7 – ident: R30 doi: 10.1038/mt.2008.36 – ident: R50 doi: 10.1007/s11095-006-9662-5 – ident: R12 doi: 10.1208/s12248-010-9174-4 – ident: R14 doi: 10.1080/10717540902937562 – ident: R15 doi: 10.1016/j.addr.2013.08.004 – ident: R9 doi: 10.1080/10258140290033066 – ident: R16 doi: 10.1016/j.bmcl.2005.07.087 – ident: R5 doi: 10.1016/0014-2999(90)91262-A – ident: R1 doi: 10.1016/S0928-0987(00)00166-4 – ident: R11 doi: 10.1016/j.jhep.2004.12.035 – ident: R31 doi: 10.1016/0092-8674(88)90263-2 – ident: R39 doi: 10.1080/10611860701498203 – volume: 7 start-page: 889 year: 2002 ident: R44 publication-title: Cell Mol Biol Lett contributor: fullname: Allen TM – ident: R46 doi: 10.1042/BJ20040238 – ident: R10 doi: 10.1016/S1368-7646(03)00082-7 – ident: R19 doi: 10.1016/S0168-3659(99)00248-5 – ident: R51 doi: 10.1124/jpet.107.127704 – ident: R6 doi: 10.1016/j.ddmec.2004.10.001 – ident: R53 doi: 10.1073/pnas.151247498 – ident: R42 doi: 10.1016/j.jconrel.2011.12.002 – volume: 57 start-page: 5246 year: 1997 ident: R8 publication-title: Cancer Res contributor: fullname: Krishna R – ident: R38 doi: 10.1021/bc900081e – ident: R47 doi: 10.1208/s12248-008-9029-4 – ident: R3 doi: 10.1208/aapsj0902015 – ident: R27 doi: 10.1016/j.jconrel.2004.08.007 – ident: R55 doi: 10.1158/1078-0432.CCR-07-4973 – ident: R17 doi: 10.1038/nrd1632 – ident: R34 doi: 10.3109/10717544.2011.567310 – ident: R49 doi: 10.1016/0005-2736(91)90246-5 – ident: R4 doi: 10.1158/0008-5472.CAN-05-0765 – ident: R7 doi: 10.1016/j.taap.2004.10.012 – volume: 16 start-page: 351 year: 2007 ident: R37 publication-title: Oncol Res doi: 10.3727/000000006783980946 contributor: fullname: Gupta B – ident: R43 doi: 10.1039/c2ib20135f – volume: 263 start-page: 16051 year: 1988 ident: R18 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)37555-0 contributor: fullname: Maeda H – ident: R25 doi: 10.1016/j.ejpb.2008.09.026 – ident: R33 doi: 10.1016/j.molmed.2012.04.012 |
SSID | ssj0027269 |
Score | 2.3552244 |
Snippet | Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have... |
SourceID | pubmedcentral proquest crossref pubmed informaworld |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 69 |
SubjectTerms | 2C5 mAb Animals Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - chemistry Antibodies, Monoclonal - chemistry Apoptosis - drug effects Cell Line, Tumor Cell Survival - drug effects doxil doxorubicin Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Doxorubicin - chemistry Drug Resistance, Neoplasm Female Heterografts Humans Lipodox Male Mice Mice, Inbred BALB C Mice, Nude multidrug resistance multifunctional immunoliposomes Nucleosomes - immunology Nucleosomes - metabolism Ovarian Neoplasms - drug therapy Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology pH-sensitive polymers Polyethylene Glycols - administration & dosage Polyethylene Glycols - chemistry Research Paper SKOV-3 cells tat Gene Products, Human Immunodeficiency Virus - chemistry TAT peptide |
Title | Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models |
URI | https://www.tandfonline.com/doi/abs/10.4161/cbt.26609 https://www.ncbi.nlm.nih.gov/pubmed/24145298 https://search.proquest.com/docview/1493796652 https://pubmed.ncbi.nlm.nih.gov/PMC3938525 |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9tAEF3iHEovpd91P8K29Lq2pN3VSseQNoSCQw8O5Cb2MxVEkrHk0J_Un9mZlRXiklNBF2sly_BGnvd2Z98Q8lWVAf2PPeMus0xwnTADocLSEGSRF0WqBW4UXl3mF1fix7W8PiJy2gsTi_atqRftbbNo61-xtnLT2OVUJ7b8uTrjJS9kJpczMoMAnST6pLKy2McuvskiEWq0E0Iev7RmWEBCStAqFDIXrjkWB_nowK30Mc75b-nkg1x0_pw825NIejr-2BfkyLcvyZPVfpn8FfnzrfvdbXcGP1I41qdrusHyFedZ07k6AO-ksZQQ09o4G0hr3CnS3dabru8a31PnG-SOaCXRw5cgu-zhNtwIgf0mqL7RNYxTA1hTt93dsB6L4fHvk-rWjadAzCNBbQfa3YEq1y21GGZbGjvw9K_J1fn39dkF27dkYFZkycBKaV2mtcut9KYALpCaIPLUF8plkO2FMTbxZerRqN47roIPqUmlUsEWmSkVf0OO26717wjVOi91AfotWCWMFYYnmQX16JUBilnKOfkyAVNtRueNChQLAlkBkFUEck7YQ8iqIU5zhLEnScUfuf7zhGkF7xEujujWd7seJBAQNdB-MpuTtyPG94-dYmVO1AH69xegR_fhCIRu9Oreh-r7_77zA3kKHE2Msz4fyfGw3flPwIMGc0JmPLk8idH_F26mEBA |
link.rule.ids | 230,315,730,783,787,888,27936,27937,53804,53806,60214,61003 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaqVgIupTy7UMAgrl7ycOLkWAHVAt09bUVvke3YJYKNV3kg1F_Ez2Qm3i1N1UulXBLn4TgzmW_smW8IeS9yi_zHhsVlpBmPZcAUiAoLrU2yNMtCyTFReL5IZ2f863lyvkPSbS4MhlWiD209UcTwr0blxslo1HDE4x-06qZgWDBvby9F0i9M3QgW_x2taChlNygzD7jwjELjS0d2aMRSehvWvBkyec0GnTwk37e996EnP6d9p6b68gax491f74Dsb2ApPfZy9IjsmPoxuTffLLw_IX8_uT-u6RXuUtiWx0u6xoCY0rCVKysLSJYOwYloKP38Iq0w98T9qtaudSvT0tKsEI0iOUULN0G82sJlmFqBFSyovJAVtFMF0kPLpr9gLYbX4w-Zwtv4Q41pEfLWHXW_wc-XNdUouA0davq0T8nZyeflxxnbFHlgmkdBx_JEl5GUZaoTozJAF6GyPA1NJsoI8ANXSgcmDw1S35syFtbYUIWJEFZnkcpF_Izs1q42h4RKmeYyA4_QasGV5ioOIg3-qBEKQGueTMi77Scv1p7LowAfCMe8gDEvhjGfEHZdGIpumDixvspJEd9y_tuttBSgmbjcImvj-hacKoB-4E0m0YQ899Jz9VjATbjinU2IGMnV1QnI-j1uqasfA_t3nMdZEiUv7tjPN-T-bDk_LU6_LL69JA8A93E_k3REdrumN68AW3Xq9aBI_wAGuSlw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JbtswECWCFAh66b443diiV7paSFE6Bk2NdInRg1PkJnBNhNaSYUlB0S_qZ3ZGtNMoyCWAL7YWS9QbzRty5g0h72XhUf_YsdQmhvFURUwDVFjsvcizPI8Vx0Lh43l2dMK_nIrTHSK2tTCYVokxtA9CEcO7Go17ZT0aONLxD0Z3U_ArWLZ3B7x_hPBOo_n_OCsZOtkNtswjLoOg0PjQkRsaiZTeRDWvZ0xecUGz--TH9uJD5snPad_pqflzTdfx1nf3gNzbkFJ6EFD0kOy4-hHZO94suz8mfw-b38261_iVwmdxsKArTIexji0bW3ngsXRITUQ3GWYXaYWVJ82vatW0zdK11LolclGUpmjhJMhWWzgMCyuwfwVVZ6qC7VQDdqhd92esxeR6fB1TuJnw09q1SHjrjjYXEOWrmhqE7ZoOHX3aJ-Rk9mnx8YhtWjwww5OoY4UwNlHKZkY4nQO3iLXnWexyaRNgD1xrE7kidih872wqvfOxjoWU3uSJLmT6lOzWTe2eE6pUVqgc4kFvJNeG6zRKDESjTmqgrIWYkHfbJ16ugpJHCREQjnkJY14OYz4h7CoWym6YNvGhx0mZ3rD_2y1YSrBLXGxRtWv6FkIqIH4QS4pkQp4F8Fz-LbAmXO_OJ0SOYHW5A2p-j7fU1fmg_Z0WaS4SsX_L63xD9r4fzspvn-dfX5C7QPp4mEZ6SXa7de9eAbHq9OvBjP4BhqEoHQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Doxorubicin+in+TAT+peptide-modified+multifunctional+immunoliposomes+demonstrates+increased+activity+against+both+drug-sensitive+and+drug-resistant+ovarian+cancer+models&rft.jtitle=Cancer+biology+%26+therapy&rft.au=Apte%2C+Anjali&rft.au=Koren%2C+Erez&rft.au=Koshkaryev%2C+Alexander&rft.au=Torchilin%2C+Vladimir+P&rft.date=2014-01-01&rft.pub=Taylor+%26+Francis&rft.issn=1538-4047&rft.eissn=1555-8576&rft.volume=15&rft.issue=1&rft.spage=69&rft.epage=80&rft_id=info:doi/10.4161%2Fcbt.26609&rft.externalDocID=10926609 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-4047&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-4047&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-4047&client=summon |